Metronomic oral vinorelbine in advanced breast cancer and non-small-cell lung cancer: Current status and future development

Marina Cazzaniga, Andrea Camerini, Raffaele Addeo, Franco Nole, Elisabetta Munzone, Elena Collovà, Alessandro Del Conte, Manlio Mencoboni, Paola Papaldo, F. Pasini, S. Saracchini, Guido Bocci

Research output: Contribution to journalArticle

Abstract

Metronomic chemotherapy (mCT), a frequent administration of low-dose chemotherapy, allows prolonged treatment duration and minimizes the toxicity of standard-dose chemotherapy. mCT has multiple actions against cancer cells including inhibition of angiogenesis and modulation of the immune system. A number of studies lend support to the clinical efficacy of mCT in advanced breast cancer and non-small-cell lung cancer. However, further evidence is necessary to describe the optimal use of mCT and to identify suitable patients. Oral vinorelbine has emerged as a promising metronomic treatment in patients with metastatic breast cancer and non-small-cell lung cancer and is the only orally available microtubule-targeting agent. This paper reviews current evidence on metronomic oral vinorelbine, discusses its management and defines a suitable patient profile on the basis of a workshop of Italian experts.

Original languageEnglish
Pages (from-to)373-387
Number of pages15
JournalFuture Oncology
Volume12
Issue number3
DOIs
Publication statusPublished - Feb 1 2016

Keywords

  • breast cancer
  • metronomic chemotherapy
  • NSCLC
  • vinorelbine

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Metronomic oral vinorelbine in advanced breast cancer and non-small-cell lung cancer: Current status and future development'. Together they form a unique fingerprint.

  • Cite this

    Cazzaniga, M., Camerini, A., Addeo, R., Nole, F., Munzone, E., Collovà, E., Del Conte, A., Mencoboni, M., Papaldo, P., Pasini, F., Saracchini, S., & Bocci, G. (2016). Metronomic oral vinorelbine in advanced breast cancer and non-small-cell lung cancer: Current status and future development. Future Oncology, 12(3), 373-387. https://doi.org/10.2217/fon.15.306